Marco Metra

Summary

Country: Italy

Publications

  1. pmc Anemia and heart failure: a cause of progression or only a consequence?
    Marco Metra
    Section of Cardiovascular Diseases Department of Experimental and Applied Medicine, University of Brescia Spedali Civili, Brescia Italy
    Heart Int 3:1. 2007
  2. doi request reprint Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes
    Marco Metra
    Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia and Civil Hospital, Brescia, Italy
    J Am Coll Cardiol 61:196-206. 2013
  3. doi request reprint The role of the kidney in heart failure
    Marco Metra
    Institute of Cardiology, University of Brescia, c o Spedali Civili di Brescia, Piazzale Spedali Civili 1, Brescia, Italy
    Eur Heart J 33:2135-42. 2012
  4. doi request reprint Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation
    Marco Metra
    Cardiology, Department of Experimental and Applied Medicine, University and Civil Hospital of Brescia, c o Spedali Civili, Piazza Spedali Civili 1, 25123 Brescia, Italy
    Clin Res Cardiol 101:663-72. 2012
  5. doi request reprint The puzzle of kidney dysfunction in heart failure: an introduction
    Marco Metra
    Institute of Cardiology, University of Brescia, Brescia, Italy
    Heart Fail Rev 17:129-31. 2012
  6. doi request reprint Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function
    Marco Metra
    Institute of Cardiology, Department of Experimental and Applied Medicine, University of Brescia, Brescia, Italy
    Circ Heart Fail 5:54-62. 2012
  7. pmc Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond
    John R Teerlink
    San Francisco Veterans Affairs Medical Center, University of California, USA
    Heart Fail Rev 14:243-53. 2009
  8. pmc Relaxin: review of biology and potential role in treating heart failure
    Sam L Teichman
    Corthera, Inc, a subsidiary of Novartis Pharmaceuticals Corp, San Mateo, CA 94402, USA
    Curr Heart Fail Rep 7:75-82. 2010
  9. ncbi request reprint [Heart rate: a risk factor or an epiphenomenon?]
    Marco Metra
    Cardiologia, Dipartimento di Medicina Sperimentale ed Applicata, Università degli Studi e Spedali Civili, Brescia
    G Ital Cardiol (Rome) 11:209-20. 2010
  10. pmc Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study
    Marco Metra
    Cardiology, Department of Experimental and Applied Medicine, University of Brescia, Brescia, Italy
    Eur J Heart Fail 12:1130-9. 2010

Detail Information

Publications111 found, 100 shown here

  1. pmc Anemia and heart failure: a cause of progression or only a consequence?
    Marco Metra
    Section of Cardiovascular Diseases Department of Experimental and Applied Medicine, University of Brescia Spedali Civili, Brescia Italy
    Heart Int 3:1. 2007
    ..Moreover a favourable effect on prognosis of the correction of anemia has not been shown, yet, and also controlled studies assessing its effects on exercise tolerance have yielded controversial results...
  2. doi request reprint Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the Relaxin in Acute Heart Failure (RELAX-AHF) development program: correlation with outcomes
    Marco Metra
    Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia and Civil Hospital, Brescia, Italy
    J Am Coll Cardiol 61:196-206. 2013
    ..The aim of this study was to assess the effects of serelaxin on short-term changes in markers of organ damage and congestion and relate them to 180-day mortality in patients with acute heart failure...
  3. doi request reprint The role of the kidney in heart failure
    Marco Metra
    Institute of Cardiology, University of Brescia, c o Spedali Civili di Brescia, Piazzale Spedali Civili 1, Brescia, Italy
    Eur Heart J 33:2135-42. 2012
    ..The prevention of renal dysfunction with new therapies might also improve outcomes although strong evidence is still lacking...
  4. doi request reprint Troponin T levels in patients with acute heart failure: clinical and prognostic significance of their detection and release during hospitalisation
    Marco Metra
    Cardiology, Department of Experimental and Applied Medicine, University and Civil Hospital of Brescia, c o Spedali Civili, Piazza Spedali Civili 1, 25123 Brescia, Italy
    Clin Res Cardiol 101:663-72. 2012
    ..With this aim, we assessed the clinical and prognostic significance of high serum cTnT levels at the time of admission and that of cTnT release in 198 consecutive patients admitted for AHF and with no signs of acute coronary syndrome...
  5. doi request reprint The puzzle of kidney dysfunction in heart failure: an introduction
    Marco Metra
    Institute of Cardiology, University of Brescia, Brescia, Italy
    Heart Fail Rev 17:129-31. 2012
    ..New biomarkers of glomerular and tubular function might allow an earlier and more accurate detection of worsening renal function...
  6. doi request reprint Is worsening renal function an ominous prognostic sign in patients with acute heart failure? The role of congestion and its interaction with renal function
    Marco Metra
    Institute of Cardiology, Department of Experimental and Applied Medicine, University of Brescia, Brescia, Italy
    Circ Heart Fail 5:54-62. 2012
    ..We hypothesized that these discrepancies may be caused by the interaction between WRF and congestion in AHF patients...
  7. pmc Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond
    John R Teerlink
    San Francisco Veterans Affairs Medical Center, University of California, USA
    Heart Fail Rev 14:243-53. 2009
    ....
  8. pmc Relaxin: review of biology and potential role in treating heart failure
    Sam L Teichman
    Corthera, Inc, a subsidiary of Novartis Pharmaceuticals Corp, San Mateo, CA 94402, USA
    Curr Heart Fail Rep 7:75-82. 2010
    ..Ongoing, large-scale clinical testing will provide additional insights into the potential role of relaxin in the treatment of heart failure...
  9. ncbi request reprint [Heart rate: a risk factor or an epiphenomenon?]
    Marco Metra
    Cardiologia, Dipartimento di Medicina Sperimentale ed Applicata, Università degli Studi e Spedali Civili, Brescia
    G Ital Cardiol (Rome) 11:209-20. 2010
    ..Further data will become available with the SHIFT trial in which patients with heart failure and HR > or =70 b/min are included and reduction in cardiovascular mortality and heart failure hospitalizations is the primary endpoint...
  10. pmc Dyspnoea and worsening heart failure in patients with acute heart failure: results from the Pre-RELAX-AHF study
    Marco Metra
    Cardiology, Department of Experimental and Applied Medicine, University of Brescia, Brescia, Italy
    Eur J Heart Fail 12:1130-9. 2010
    ..Although dyspnoea is the most common cause of admission for acute heart failure (AHF), more needs to be known about its clinical course and prognostic significance...
  11. ncbi request reprint Influence of heart rate, blood pressure, and beta-blocker dose on outcome and the differences in outcome between carvedilol and metoprolol tartrate in patients with chronic heart failure: results from the COMET trial
    Marco Metra
    Cattedra di Cardiologia, Universita di Brescia, Italy
    Eur Heart J 26:2259-68. 2005
    ....
  12. doi request reprint Cardiovascular and noncardiovascular comorbidities in patients with chronic heart failure
    Marco Metra
    Cardiology, Department of Experimental and Applied Medicine, University of Brescia, Brescia, Italy
    J Cardiovasc Med (Hagerstown) 12:76-84. 2011
    ..In this review we provide an updated summary of the epidemiological, pathophysiological and clinical characteristics of comorbidities as well as their potential impact for heart failure treatment...
  13. ncbi request reprint Role of beta1- and alpha2c-adrenergic receptor polymorphisms and their combination in heart failure: a case-control study
    Marco Metra
    Institute of Cardiology, Department of Experimental and Applied Medicine, University of Brescia, Brescia, Italy
    Eur J Heart Fail 8:131-5. 2006
    ..We hypothesised that these polymorphisms could influence the prevalence of heart failure...
  14. doi request reprint Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure
    Marco Metra
    Institute of Cardiology, Department of Experimental and Applied Medicine, University of Brescia, Italy
    Cardiovasc Drugs Ther 24:49-60. 2010
    ..Beta-adrenergic receptors (AR) single nucleotide gene polymorphisms (SNPs) may influence the sensitivity and density of beta-AR. We assessed the relation between three common beta-AR SNPs and the response to carvedilol administration...
  15. doi request reprint Dyspnoea in patients with acute heart failure: an analysis of its clinical course, determinants, and relationship to 60-day outcomes in the PROTECT pilot study
    Marco Metra
    Cardiology, University of Brescia, P zza Spedali Civili, Brescia 25100, Italy
    Eur J Heart Fail 12:499-507. 2010
    ..Dyspnoea is the most common symptom leading to hospitalization for acute heart failure (AHF). Its early and persistent relief is an important goal of therapy, but little is known about its course, determinants, and prognostic significance...
  16. doi request reprint Acute heart failure: multiple clinical profiles and mechanisms require tailored therapy
    Marco Metra
    Cardiology, Department of Experimental and Applied Medicine, University of Brescia, Italy
    Int J Cardiol 144:175-9. 2010
    ..Different pathophysiologic mechanisms and clinical presentations may coexist in the same patient. Identification and, whenever possible, treatment of underlying pathophysiologic mechanisms may become important for acute HF management...
  17. ncbi request reprint Beta-blocker therapy of heart failure: an update
    Marco Metra
    University of Brescia c o Cardiologia, Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, Spedali Civili, P zza Spedali Civili 125123 Brescia, Italy
    Expert Opin Pharmacother 8:289-98. 2007
    ....
  18. ncbi request reprint Clinical trials update from the World Congress of Cardiology 2006
    Marco Metra
    University of Brescia c o Spedali Civili, Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, P zza Spedali Civili 1, 25123 Brescia, Italy
    Expert Opin Pharmacother 8:881-9. 2007
    ..Finally, the results of other trials of percutaneous patent foramen ovale closure and atrial fibrillation treatment in elderly patients are summarised...
  19. ncbi request reprint Advanced chronic heart failure: A position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology
    Marco Metra
    Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy
    Eur J Heart Fail 9:684-94. 2007
    ..These patients deserve effective therapeutic options and should be potential targets for future clinical research initiatives...
  20. ncbi request reprint The role of plasma biomarkers in acute heart failure. Serial changes and independent prognostic value of NT-proBNP and cardiac troponin-T
    Marco Metra
    Section on Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy
    Eur J Heart Fail 9:776-86. 2007
    ..Brain natriuretic peptide (BNP), NT-proBNP and troponins are useful for the assessment of patients with heart failure. Few data exist about their serial changes and their prognostic value in patients with acute heart failure (AHF)...
  21. ncbi request reprint Should beta-blocker therapy be reduced or withdrawn after an episode of decompensated heart failure? Results from COMET
    Marco Metra
    Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy
    Eur J Heart Fail 9:901-9. 2007
    ..We studied the relationship between changes in beta-blocker dose and outcome in patients surviving a HF hospitalisation in COMET...
  22. ncbi request reprint [The CORONA study]
    Marco Metra
    Sezione di Malattie Cardiovascolari, Dipartimento di Medicina Sperimentale ed Applicata, Universita degli Studi, Brescia
    G Ital Cardiol (Rome) 9:229-33. 2008
  23. pmc Vasodilators in the treatment of acute heart failure: what we know, what we don't
    Marco Metra
    Department of Experimental and Applied Medicine, University of Brescia, Italy
    Heart Fail Rev 14:299-307. 2009
    ..Given the limitations of the currently available clinical trial data, we cannot recommend any specific agent as first line therapy, although nitrates in different formulations are still the most widely used in clinical practice...
  24. ncbi request reprint [Acute heart failure: clinical profiles and pathophysiology]
    Marco Metra
    Cattedra di Cardiologia, Dipartimento di Medicina Sperimentale ed Applicata, Universita degli Studi, Brescia
    G Ital Cardiol (Rome) 9:105S-111S. 2008
    ..Identification and, whenever possible, treatment of underlying pathophyisiological mechanisms should be a primary objective of acute HF management...
  25. pmc Effects of low-dose oral enoximone administration on mortality, morbidity, and exercise capacity in patients with advanced heart failure: the randomized, double-blind, placebo-controlled, parallel group ESSENTIAL trials
    Marco Metra
    Cardiology, Department of Experimental and Applied Medicine, c o Spedali Civili, University of Brescia, P zza Spedali Civili, 25100 Brescia, Italy
    Eur Heart J 30:3015-26. 2009
    ....
  26. doi request reprint Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance
    Marco Metra
    Section on Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy
    Eur J Heart Fail 10:188-95. 2008
    ..Renal function is a powerful prognostic variable in patients with heart failure (HF). Hospitalisations for acute HF (AHF) may be associated with further worsening of renal function (WRF)...
  27. ncbi request reprint [Beta-blockers in the treatment of heart failure]
    Marco Metra
    Cattedra di Cardiologia, Universita degli Studi, Brescia
    Ital Heart J 6:46S-52S. 2005
  28. doi request reprint Can we improve the treatment of congestion in heart failure?
    Marco Metra
    University of Brescia, Cardiology, Department of Experimental and Applied Medicine Spedali Civili, Piazzale Spedali Civili, Italy
    Expert Opin Pharmacother 12:1369-79. 2011
    ..Treatment of fluid overload should relieve symptoms and have a neutral or favorable effect on outcomes...
  29. ncbi request reprint Marked improvement in left ventricular ejection fraction during long-term beta-blockade in patients with chronic heart failure: clinical correlates and prognostic significance
    Marco Metra
    Cattedra di Cardiologia, Universita di Brescia, Italy
    Am Heart J 145:292-9. 2003
    ..We compared the clinical characteristics and the prognosis of these patients with those of other patients...
  30. ncbi request reprint [Heart failure: should treatment favor prognosis or quality of life? Opinion... in favor of prognosis]
    Marco Metra
    Cattedra di Cardiologia Università degli Studi Spedali Civili Piazzale Spedali Civili, 1 25123 Brescia
    Ital Heart J 3:47S-50S. 2002
  31. doi request reprint Old and new intravenous inotropic agents in the treatment of advanced heart failure
    Marco Metra
    Cardiology, Department of Experimental and Applied Medicine, University of Brescia, Civil Hospital of Brescia, Italy
    Prog Cardiovasc Dis 54:97-106. 2011
    ..We have summarized the characteristics of the main inotropic agents for heart failure treatment, the data from randomized controlled trials, and future perspectives for this class of drugs...
  32. ncbi request reprint Beta-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol
    Marco Metra
    Cattedra di Cardiologia, Universita di Brescia, Brescia, Italy
    J Am Coll Cardiol 40:1248-58. 2002
    ..We compared the hemodynamic effects of dobutamine and enoximone administration before and after long-term beta-blocker therapy with metoprolol or carvedilol in patients with chronic heart failure (HF)...
  33. doi request reprint Use of inotropic agents in patients with advanced heart failure: lessons from recent trials and hopes for new agents
    Marco Metra
    Institute of Cardiology, Department of Experimental and Applied Medicine, University of Brescia, Brescia, Italy
    Drugs 71:515-25. 2011
    ..These characteristics might allow a haemodynamic improvement in the absence of untoward effects on the clinical course and prognosis of the patients...
  34. ncbi request reprint [Dilated cardiomyopathy: indication and role of invasive evaluation]
    Marco Metra
    Cattedra di Cardiologia Università degli Studi, Piazzale Spedali Civili, 1 25123 Brescia
    Ital Heart J Suppl 3:412-8. 2002
    ..Coronary angiography is also indicated in all the patients who are candidates to heart transplantation or whose symptoms are secondary to a mechanical complication of myocardial infarction...
  35. ncbi request reprint Beta-blockade in heart failure: selective versus nonselective agents
    M Metra
    Department of Cardiology, University of Brescia, Brescia, Italy
    Am J Cardiovasc Drugs 1:3-14. 2001
    ....
  36. ncbi request reprint [New and old beta-blockers in the treatment of heart failure]
    Marco Metra
    Cattedra di Cardiologia, Universita, Brescia
    Recenti Prog Med 93:113-24. 2002
    ..It is however, unclear whether these differences may also influence the patients' outcome...
  37. ncbi request reprint [Treatment of heart failure patients with inotropic drugs: beyond traditional agents]
    Marco Metra
    Cardiologia, Dipartimento di Medicina Sperimentale ed Applicata, Universita degli Studi, Spedali Civili, Brescia
    G Ital Cardiol (Rome) 11:143S-148S. 2010
    ..Further studies are, however, needed...
  38. ncbi request reprint [Plasma brain natriuretic peptide levels in the diagnostic and prognostic assessment of patients with heart failure. Pros]
    Marco Metra
    Cattedra e U O di Cardiologia, Universita degli Studi, Spedali Civili, Brescia
    Ital Heart J 4:59S-67S. 2003
  39. ncbi request reprint Differential effects of beta-blockers in patients with heart failure: A prospective, randomized, double-blind comparison of the long-term effects of metoprolol versus carvedilol
    M Metra
    Cattedra di Cardiologia, Universita di Brescia, Italy
    Circulation 102:546-51. 2000
    ....
  40. ncbi request reprint Beta-blockers in heart failure: are pharmacological differences clinically important?
    Marco Metra
    Cattedra di Cardiologia, Universita di Brescia, c o Spedali Civili, P zza Spedali Civili, 25123 Brescia, Italy
    Heart Fail Rev 9:123-30. 2004
    ..However, also more effective and prolonged blockade of beta1 adrenergic receptors may occur with carvedilol compared to metoprolol...
  41. ncbi request reprint Current guidelines in the pharmacological management of chronic heart failure
    Marco Metra
    Cardiologia, Universita di Brescia, 25123, Italy
    J Renin Angiotensin Aldosterone Syst 5:S11-6. 2004
    ..Prevention of heart failure has also become a major goal. We summarise here the major issues regarding the pharmacological treatment of chronic heart failure as indicated by the European and US guidelines...
  42. ncbi request reprint Efficacy and tolerability of the long-term administration of carvedilol in patients with chronic heart failure with and without concomitant diabetes mellitus
    Savina Nodari
    Cattedra di Cardiologia, Universita di Brescia, Piazza Spedali Civili, 25100 Brescia, Italy
    Eur J Heart Fail 5:803-9. 2003
    ..Diabetes is frequently associated with heart failure and is an independent risk factor for an increased mortality and morbidity. Beta-blockers are traditionally regarded as relatively contraindicated in patients with diabetes mellitus...
  43. ncbi request reprint Exchange of beta-blockers in heart failure patients. Experiences from the poststudy phase of COMET (the Carvedilol or Metoprolol European Trial)
    Andrea Di Lenarda
    Department of Cardiology, Ospedale di Cattinara, Strada di Fiume 447, 34100 Trieste, Italy
    Eur J Heart Fail 7:640-9. 2005
    ..metoprolol tartrate, a beta1-selective blocker, in patients with mild-to-severe chronic heart failure (CHF). Patients on treatment with metoprolol might benefit from switching to carvedilol...
  44. ncbi request reprint Role of beta1- and beta2-adrenoceptor polymorphisms in heart failure: a case-control study
    Loredana Covolo
    Cattedra di Igiene, Universita di Brescia, Italy
    Eur Heart J 25:1534-41. 2004
    ..We therefore compared the polymorphisms of the beta1-adrenoceptor gene (Arg389Gly), the beta2-adrenoceptor gene (Arg16Gly, Gln27Glu) and their combinations in patients with HF and normal subjects living in the same area...
  45. doi request reprint Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure
    Enrico Vizzardi
    Department of Cardiology, University of Brescia, Italy
    Am J Cardiol 106:1292-6. 2010
    ..Cardiopulmonary exercise testing parameters did not change. In conclusion, administration of spironolactone to patients with NYHA class I to II HF has beneficial effects on LV remodeling and diastolic function...
  46. doi request reprint Can we prevent or treat renal dysfunction in acute heart failure?
    Valentina Lazzarini
    Department of Experimental and Applied Medicine, Section of Cardiovascular Diseases, University of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy
    Heart Fail Rev 17:291-303. 2012
    ..In this review, we focus on the strategies to detect renal dysfunction in acute HF, the underlying pathophysiological mechanisms, and the potential treatments...
  47. ncbi request reprint Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS)
    John R Teerlink
    San Francisco Veterans Affairs Medical Center, University of California, San Francisco, California, USA
    Am Heart J 150:46-53. 2005
    ..Tezosentan, an intravenous endothelin receptor antagonist, improved hemodynamics in patients with AHF; however, its effects on morbidity and mortality have not been evaluated...
  48. doi request reprint Measurement of the myocardial performance index in ambulatory patients with heart failure: correlation with other clinical and echocardiographic parameters and independent prognostic value
    Enrico Vizzardi
    Department of Experimental and Applied Medicine, Section of Cardiovascular Diseases, University of Brescia, Brescia, Italy
    Echocardiography 27:123-9. 2010
    ..We assessed the correlation with other clinical and echocardiographic measurements and the prognostic value of MPI in patients with HF...
  49. ncbi request reprint Serum levels of carbohydrate antigen 125 in patients with chronic heart failure: relation to clinical severity, hemodynamic and Doppler echocardiographic abnormalities, and short-term prognosis
    Antonio D'Aloia
    Cattedra di Cardiologia, Universita di Brescia, Brescia, Italy
    J Am Coll Cardiol 41:1805-11. 2003
    ..The aim of this study was to evaluate the serum levels of carbohydrate antigen 125 (CA125) in patients with congestive heart failure (CHF)...
  50. doi request reprint Early dyspnoea relief in acute heart failure: prevalence, association with mortality, and effect of rolofylline in the PROTECT Study
    Marco Metra
    Cardiology, Department of Experimental and Applied Medicine, University of Brescia, Brescia, Italy
    Eur Heart J 32:1519-34. 2011
    ..We have assessed changes in dyspnoea, their relationship with mortality, and the effects of the adenosine A1 receptor antagonist rolofylline on these endpoints in patients enrolled in the PROTECT trial...
  51. doi request reprint Six-year prognosis of diabetic patients with coronary artery disease
    Savina Nodari
    Section of Cardiology, Department of Experimental and Applied Sciences, University of Brescia, Brescia, Italy
    Eur J Clin Invest 42:376-83. 2012
    ..The aim of our study was to determine the prognostic factors for mortality in patients with type 2 diabetes (T2DM) and coronary artery disease (CAD) who underwent coronary angiography and percutaneous coronary intervention...
  52. doi request reprint Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study
    John R Teerlink
    Section of Cardiology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA, USA
    Lancet 373:1429-39. 2009
    ..We assessed the dose response of relaxin's effect on symptom relief, other clinical outcomes, and safety...
  53. ncbi request reprint [Prognostic evaluation in patients with heart failure]
    Enrico Vizzardi
    Cattedra e U O di Cardiologia, Universita degli Studi, Brescia
    Ital Heart J Suppl 4:720-6. 2003
    ....
  54. doi request reprint Renal dysfunction in acute heart failure: epidemiology, mechanisms and assessment
    Valentina Carubelli
    Cardiology, c o Spedali Civili di Brescia, University of Brescia, Piazzale Spedali Civili 1, 25123 Brescia, Italy
    Heart Fail Rev 17:271-82. 2012
    ..New biomarkers of renal injury seem promising but still need to be validated. Thus, despite the epidemiological evidence, we are still lacking of satisfactory tools to assess renal injury and function and its prognostic significance...
  55. doi request reprint Hyponatremia and long-term outcomes in chronic heart failure--an observational study from the Duke Databank for Cardiovascular Diseases
    Luca Bettari
    Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Brescia, Italy
    J Card Fail 18:74-81. 2012
    ..Hyponatremia is a well known predictor of short-term outcomes in heart failure (HF); however, its impact on long-term survival in HF patients with systolic dysfunction is not well established...
  56. pmc Bisoprolol in the treatment of chronic heart failure: from pathophysiology to clinical pharmacology and trial results
    Marco Metra
    Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia Italy
    Ther Clin Risk Manag 3:569-78. 2007
    ..This article will summarize evidence for the efficacy of bisoprolol in the treatment of HF...
  57. ncbi request reprint Prevention and management of chronic heart failure in patients at risk
    Livio Dei Cas
    Cattedra di Cardiologia, Universita di Brescia, Brescia, Italy
    Am J Cardiol 91:10F-17F. 2003
    ..The role of antiplatelet agents, warfarin, and statins is clear in the prevention of the coronary artery disease. However, it has not been adequately assessed in patients with HF and awaits the results of ongoing trials...
  58. doi request reprint CA 125 tumoral marker plasma levels relate to systolic and diastolic ventricular function and to the clinical status of patients with chronic heart failure
    Enrico Vizzardi
    Institute of Cardiology, University of Brescia, Italy
    Echocardiography 25:955-60. 2008
    ..CA 125 could be used as an additional, noninvasive, easily determinable, and low-cost marker of the clinical condition of patients affected by heart failure...
  59. ncbi request reprint Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol
    Savina Nodari
    Cattedra di Cardiologia, Universita di Brescia, c o Spedali Civili, Piazza Spedali Civili, 25100 Brescia, Italy
    Eur J Heart Fail 5:621-7. 2003
    ..Thus, although the two beta-blockers have a similar antihypertensive action, nebivolol administration was associated with a greater hemodynamic improvement, compared to atenolol...
  60. ncbi request reprint Usefulness of cardiac calcification on two-dimensional echocardiography for distinguishing ischaemic from nonischaemic dilated cardiomyopathy: a preliminary report
    Pompilio Faggiano
    Laboratorio di Ecocardiografia, Spedali Civili and Cattedra di Cardiologia, Universita di Brescia, Brescia, Italy
    J Cardiovasc Med (Hagerstown) 7:182-7. 2006
    ..Aortic valve calcification (AVC) and/or mitral annulus calcification (MAC) is considered to be a marker of atherosclerosis and has been demonstrated to predict cardiovascular morbidity and mortality...
  61. ncbi request reprint Off-pump coronary artery bypass surgery technique for total arterial myocardial revascularization: a prospective randomized study
    Claudio Muneretto
    Division of Cardiac Surgery, University of Brescia Medical School, Brescia, Italy
    Ann Thorac Surg 76:778-82; discussion 783. 2003
    ..We investigated whether off-pump coronary artery bypass (OPCAB) surgery should be the procedure of choice in total arterial myocardial revascularization with composite grafts...
  62. pmc Effects of serelaxin in subgroups of patients with acute heart failure: results from RELAX-AHF
    Marco Metra
    Cardiology, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia, Brescia, Italy
    Eur Heart J 34:3128-36. 2013
    ..We have assessed possible differences in the effects of serelaxin on dyspnoea relief, 60 Day outcomes and 180 Day mortality across patient subgroups in the RELAX-AHF trial...
  63. doi request reprint The role of n-3 PUFAs in preventing the arrhythmic risk in patients with idiopathic dilated cardiomyopathy
    Savina Nodari
    Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, c o Spedali Civili, P zza Spedali Civili, 25100, Brescia, Italy
    Cardiovasc Drugs Ther 23:5-15. 2009
    ..Their effects in patients with heart failure caused by idiopathic dilated cardiomyopathy (IDC) are unknown...
  64. doi request reprint Successful switch to sitaxsentan in a patient with HIV-related pulmonary arterial hypertension and late intolerance to nonselective endothelin receptor blockade
    Valerio Zaca
    Section on Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia, Italy
    Ther Adv Respir Dis 3:11-4. 2009
    ..We report the case of a successful switch to sitaxsentan in a HIV-infected patient with PAH initially receiving bosentan who developed a late treatment-related side-effect...
  65. ncbi request reprint Total arterial myocardial revascularization with composite grafts improves results of coronary surgery in elderly: a prospective randomized comparison with conventional coronary artery bypass surgery
    Claudio Muneretto
    Division of Cardiac Surgery, University of Brescia Medical School, Brescia, Italy
    Circulation 108:II29-33. 2003
    ..We assessed the hypothesis that full arterial revascularization (FAR) may improve clinical outcome even in elderly and at short term...
  66. doi request reprint Right ventricular thrombus and pulmonary thromboembolism/thrombosis in Behçet's disease: a case report
    Ermanna Chiari
    Section of Cardiovascular Disease, Department of Applied Experimental Medicine, Brescia Study University, Brescia, Italy
    J Am Soc Echocardiogr 21:1079. 2008
    ..This case provides a rare example of BD, in which we found-at the same time-heart and pulmonary manifestations, with the presence of right ventricular thrombus and pulmonary thrombi in situ...
  67. doi request reprint Elastic properties of the ascending aorta in patients with α1-antitrypsin deficiency (Z homozygotes)
    Enrico Vizzardi
    Cattedra di Cardiologia, Dipartimento di Medicina Sperimentale e Applicata, Universita di Brescia, Italy
    Heart 98:1354-8. 2012
    ....
  68. ncbi request reprint Is total arterial myocardial revascularization with composite grafts a safe and useful procedure in the elderly?
    Claudio Muneretto
    Department of Cardiac Surgery, University of Brescia Medical School, Brescia, Italy
    Eur J Cardiothorac Surg 23:657-64; discussion 664. 2003
    ....
  69. ncbi request reprint [Mechanical circulatory supports for the treatment of advanced heart failure]
    Livio Dei Cas
    Cattedra di Cardiologia, Dipartimento di Medicina Sperimentale ed Applicata, Universita degli Studi, Brescia
    G Ital Cardiol (Rome) 9:99S-104S. 2008
    ..It appears likely, however, that mechanical circulatory supports will play a major role in the management of patients with advanced HF...
  70. doi request reprint n-3 PUFAs and cardiovascular disease prevention
    Alessandra Manerba
    Department of Cardiology, University of Brescia, Piazza del Mercato, Italy
    Future Cardiol 6:343-50. 2010
    ..Further studies are needed to determine optimal dosing and the relative ratio of DHA and EPA that provide maximal cardioprotection...
  71. pmc The combination of Ezetimibe and Statin: a new treatment for hypercholesterolemia
    Savina Nodari
    Section on Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia Italy
    Heart Int 3:12. 2007
    ..This article will review clinical experience with ezetimibe/simvastatin combination, commenting upon its place and potential value in the prevention of cardiovascular disease...
  72. pmc Endocannabinoids and cardiovascular prevention: real progress?
    Savina Nodari
    Section of Cardiovascular Diseases, Department of Experimental and Applied Medicine, University of Brescia Italy
    Heart Int 3:27. 2007
    ..The EC system represents a new target for weight control and the improvement of lipid and glycemic metabolism (6, 7)...
  73. ncbi request reprint A rationale for the use of beta-blockers as standard treatment for heart failure
    M Metra
    Cattedra di Cardiologia, Universita di Brescia, Brescia, Italy
    Am Heart J 139:511-21. 2000
    ..beta-Blockers are the most effective tool to counteract the untoward effects of sympathetic activation on the cardiovascular system...
  74. ncbi request reprint Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine
    M Metra
    Cattedra di Cardiologia, Universita di Brescia, Italy
    J Cardiovasc Pharmacol 25:732-40. 1995
    ..Dihydroergotoxine administration induced only a significant 9% decrease in mean arterial pressure (MAP), with a 13% reduction in SVR.(ABSTRACT TRUNCATED AT 250 WORDS)..
  75. doi request reprint Nuclear cardiology and heart failure
    Raffaele Giubbini
    Department of Nuclear Medicine, University of Brescia, Piazza Spedali Civili 1, 25123 Brescia, Italy
    Eur J Nucl Med Mol Imaging 36:2068-80. 2009
    ..MIBG scanning has a very promising prognostic value in patients with heart failure...
  76. ncbi request reprint [Effects of amrinone on isolated heart preparations: comparative study with other inotropic agents]
    R Raddino
    Cattedra di Cardiologia, Universita degli Studi, Brescia e Parma
    Cardiologia 36:729-34. 1991
    ..Ouabain has a less potent positive inotropic activity and a slight negative chronotropic action, whereas xamoterol inotropic effect is accompanied by an increase of heart rate.(ABSTRACT TRUNCATED AT 250 WORDS)..
  77. ncbi request reprint Use of cardiopulmonary exercise testing with hemodynamic monitoring in the prognostic assessment of ambulatory patients with chronic heart failure
    M Metra
    Cattedra di Cardiologia, Universita di Brescia, Italy
    J Am Coll Cardiol 33:943-50. 1999
    ....
  78. ncbi request reprint Prognostic relevance of atrial fibrillation in patients with chronic heart failure on long-term treatment with beta-blockers: results from COMET
    Karl Swedberg
    Department of Medicine, Sahlgrenska University Hospital Ostra, SE 416 85 Goteborg, Sweden
    Eur Heart J 26:1303-8. 2005
    ..Atrial fibrillation is common in patients with chronic heart failure (CHF). We analysed the risk associated with atrial fibrillation in a large cohort of patients with chronic heart failure all treated with a beta-blocker...
  79. ncbi request reprint [Pharmacological therapy of chronic heart failure in the elderly]
    Gastone Sabbadini
    Struttura Complessa di Cardiologia, Dipartimento di Scienze Cliniche, Morfologiche e Tecnologiche, Universita degli Studi, Trieste
    Ital Heart J 5:37S-51S. 2004
    ..Finally, the development of new multidisciplinary and effective models for the management of the ever-growing number of patients with heart failure is of utmost urgency...
  80. ncbi request reprint Effects of metoprolol and carvedilol on cause-specific mortality and morbidity in patients with chronic heart failure--COMET
    Christian Torp-Pedersen
    Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark
    Am Heart J 149:370-6. 2005
    ..Beta-blockers with different receptor bindings reduce mortality in patients with chronic heart failure. We compared the effects of the beta1-blocker metoprolol tartrate and the beta1-, beta2-, and alpha1-blocker carvedilol...
  81. ncbi request reprint Symptoms in patients with heart failure are prognostic predictors: insights from COMET
    Inger Ekman
    Institute of Nursing, Sahlgrenska Academy at Goteborg University, SE 405 30 Goteborg, Sweden
    J Card Fail 11:288-92. 2005
    ....
  82. ncbi request reprint Executive summary of the guidelines on the diagnosis and treatment of acute heart failure: the Task Force on Acute Heart Failure of the European Society of Cardiology
    Markku S Nieminen
    Division of Cardiology, Helsinki University Central Hospital, Haartmaninkatu 4, 00290 Helsinki, Finland
    Eur Heart J 26:384-416. 2005
  83. ncbi request reprint A description of the clinical characteristics at baseline of patients recruited into the Carvedilol or Metoprolol European Trial (COMET)
    John G F Cleland
    University of Hull, Kingston upon Hull, UK
    Cardiovasc Drugs Ther 18:139-52. 2004
    ..The purpose of this report is to describe in greater detail the heterogeneity of this population at baseline with particular reference to the impact of symptomatic severity, age and gender on patient characteristics...
  84. ncbi request reprint Left internal thoracic artery-radial artery composite grafts as the technique of choice for myocardial revascularization in elderly patients: a prospective randomized evaluation
    Claudio Muneretto
    Division of Cardiac Surgery, University of Brescia Medical School, Italy
    J Thorac Cardiovasc Surg 127:179-84. 2004
    ..We evaluated the potential advantages of the use of left internal thoracic artery-radial artery composite grafts compared with conventional coronary artery bypass grafts in elderly patients...
  85. ncbi request reprint Rationale and design of the carvedilol or metoprolol European trial in patients with chronic heart failure: COMET
    Philip A Poole-Wilson
    Cardiac Medicine, National Heart and Lung Institute, Faculty of Medicine, Imperial College, Dovehouse Street, London, SW3 6LY, UK
    Eur J Heart Fail 4:321-9. 2002
    ..The target dose for carvedilol is 25 mg bid and for metoprolol tartrate 50 mg bid. This manuscript outlines the rationale, design and possible outcomes of COMET...
  86. ncbi request reprint Prognostic importance of plasma NT-pro BNP in chronic heart failure in patients treated with a beta-blocker: results from the Carvedilol Or Metoprolol European Trial (COMET) trial
    Lars G Olsson
    Department of Emergency and Cardiovascular Medicine Sahlgrenska Academy, Goteborg University, Goteborg, Sweden, and Department of Cardiology, La Pitie Salpetriere Hospital, Paris, France
    Eur J Heart Fail 9:795-801. 2007
    ..Beta-blockers (BB) may influence these levels but it is unclear whether changes in NT-pro BNP reflect concomitant changes in prognosis...
  87. ncbi request reprint Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial
    Philip A Poole-Wilson
    National Heart and Lung Institute, Imperial College, London, UK
    Lancet 362:7-13. 2003
    ..We aimed to compare the effects of carvedilol and metoprolol on clinical outcome...
  88. ncbi request reprint Carvedilol protects better against vascular events than metoprolol in heart failure: results from COMET
    Willem J Remme
    Sticares Cardiovascular Research Institute, Rhoon, The Netherlands
    J Am Coll Cardiol 49:963-71. 2007
    ..We explored whether vascular protection by carvedilol could contribute to its superior effects in the treatment of heart failure (HF) compared with metoprolol tartrate in the COMET (Carvedilol Or Metoprolol European Trial) study...
  89. pmc Effects of metoprolol and carvedilol on pre-existing and new onset diabetes in patients with chronic heart failure: data from the Carvedilol Or Metoprolol European Trial (COMET)
    Christian Torp-Pedersen
    Department of Cardiology, Bispebjerg University Hospital, Copenhagen NV, Denmark
    Heart 93:968-73. 2007
    ..Beta blocker treatment may worsen glucose metabolism...
  90. ncbi request reprint Optimal pharmacologic and non-pharmacologic management of cardiac transplant candidates: approaches to be considered prior to transplant evaluation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant can
    Mariell Jessup
    International Society for Heart and Lung Transplantation, Addison, Texas 75001, USA
    J Heart Lung Transplant 25:1003-23. 2006
  91. ncbi request reprint The safety of amiodarone in patients with heart failure
    Christian Torp-Pedersen
    Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark
    J Card Fail 13:340-5. 2007
    ..Uncertainty persists about the safety and efficacy of amiodarone for the management of heart failure...
  92. ncbi request reprint Effect of carvedilol and metoprolol on the mode of death in patients with heart failure
    Willem J Remme
    Sticares Cardiovascular Research Foundation, PO Box 882, 3160 AB Rhoon, The Netherlands
    Eur J Heart Fail 9:1128-35. 2007
    ..In the COMET study, carvedilol improved survival compared to metoprolol tartrate in 3029 patients with NYHA II-IV heart failure and EF <35%, followed for an average of 58 months...
  93. ncbi request reprint Low-dose oral enoximone enhances the ability to wean patients with ultra-advanced heart failure from intravenous inotropic support: results of the oral enoximone in intravenous inotrope-dependent subjects trial
    Arthur M Feldman
    Department of Medicine, Jefferson Medical College, Philadelphia, PA 19107, USA
    Am Heart J 154:861-9. 2007
    ..v.) inotropic support. Chronic parenteral inotropic therapy in UA-HF is costly and requires an indwelling catheter. An effective and safe oral inotrope would have value...
  94. ncbi request reprint The pathophysiology of acute heart failure--it is a lot about fluid accumulation
    Marco Metra
    Am Heart J 155:1-5. 2008
  95. pmc Long-term survival in patients undergoing cardiac resynchronization therapy: the importance of performing atrio-ventricular junction ablation in patients with permanent atrial fibrillation
    Maurizio Gasparini
    Electrophysiology and Pacing Unit, IRCCS Istituto Clinico Humanitas Rozzano Milano, Via Manzoni 56, Rozzano, Milano IT 2089, Italy
    Eur Heart J 29:1644-52. 2008
    ..To investigate the effects of cardiac resynchronization therapy (CRT) on survival in heart failure (HF) patients with permanent atrial fibrillation (AF) and the role of atrio-ventricular junction (AVJ) ablation in these patients...
  96. ncbi request reprint Prognostic value of cardiopulmonary exercise variables in chronic heart failure patients with or without beta-blocker therapy
    Jean Yves Tabet
    Department of Cardiology, Assistance Publique Hopitaux de Paris, Hopital Lariboisiere, Paris, France
    Am J Cardiol 98:500-3. 2006
    ....
  97. ncbi request reprint The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET
    Michel Komajda
    Institut de Cardiologie, Hopital Pitie Salpetriere, Universite Pierre et Marie Curie, 47 83 bld de l Hôpital, Paris, France
    Eur Heart J 27:1440-6. 2006
    ..Anaemia is a common comorbidity in chronic heart failure (CHF). The predictors of new onset anaemia (NOA) and its long-term prognostic value, particularly in patients treated with beta-blockers, are not known...
  98. ncbi request reprint A comparison of the effects of carvedilol and metoprolol on well-being, morbidity, and mortality (the "patient journey") in patients with heart failure: a report from the Carvedilol Or Metoprolol European Trial (COMET)
    John G F Cleland
    Department of Cardiology, University of Hull, Kingston upon Hull, United Kingdom
    J Am Coll Cardiol 47:1603-11. 2006
    ..This study was designed to investigate the loss of well-being, in terms of life-years, overall and in patients randomized to metoprolol versus carvedilol in the Carvedilol Or Metoprolol European Trial (COMET)...
  99. ncbi request reprint Rationale and design of the enoximone clinical trials program
    Brian D Lowes
    University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Card Fail 11:659-69. 2005
    ..Based on these data, the ability of enoximone to deliver safe and efficacious palliative treatment of advanced/ultra-advanced chronic heart failure is being evaluated in Phase III clinical trials...
  100. ncbi request reprint Pharmacokinetic and pharmacodynamic characteristics of beta-blockers: when differences may matter
    Marco Metra
    J Card Fail 12:177-81. 2006
  101. ncbi request reprint ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Com
    Douglas P Zipes
    J Am Coll Cardiol 48:e247-346. 2006